Selank
Women's HealthCycle-aware, fertility-aware, perimenopause-aware: Selank is evaluated by women's-health clinicians on multiple axes. Modulates GABA-A receptor systems indirectly Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines.. The compound's tuftsin-derived heptapeptide anxiolytic pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.
Key Takeaways
Female-physiology lens: Selank response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause. Mechanism: Modulates GABA-A receptor systems indirectly. Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default. Female dose: 300 mcg per spray; 2-3 sprays daily daily for 2-4 week courses via intranasal/subq; cycle-phase tracking for 1-2 cycles. Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.
Modulates GABA-A receptor systems indirectly. Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. Selank's contribution to each varies; the subsections below work through these in turn.
Perimenopause and menopause integration
For women in the perimenopausal or post-menopausal window, Selank is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.
Bone density and cardiovascular signalling
Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Selank's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.
Fertility and reproductive considerations
Selank's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.
For autoimmune support in female users, Selank is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
In the perimenopausal window, Selank for body composition (female) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
Menopause is one of the dimensions on which women track Selank response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.
For endometriosis support in female users, Selank is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | Intranasal | 300 mcg per spray; 2-3 sprays daily | 8–12 weeks on / 4 weeks off |
| Conservative starter | Intranasal | 180 mcg per spray; 2-3 sprays daily | 4–6 weeks initial cycle |
| Women's Health focus | Intranasal | 300 mcg per spray; 2-3 sprays daily | Daily for 2-4 week courses |
| Maintenance phase | Intranasal | 210 mcg per spray; 2-3 sprays daily | Ongoing with periodic pauses |
Dose timing for Selank is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Selank stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.
- Selank + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Selank's mechanism in female physiology protocols.
- Selank + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Selank's mechanism in female physiology protocols.
- Selank + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Selank's mechanism in female physiology protocols.
- Selank + Epithalon: Identified by Khavinson in St. Pairs naturally with Selank's mechanism in female physiology protocols.
Excellent. No reported dependence. Mild nasal irritation possible.
Lens-specific safety considerations for female physiology use of Selank: Excellent. No reported dependence. Mild nasal irritation possible. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | Women's Health |
| Oxytocin | Posterior pituitary nonapeptide | ~1-6 min plasma; CNS longer | The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
Can I use Selank during pregnancy or while trying to conceive?
Best monitoring labs for female users?
Can I use Selank alongside HRT?
Is Selank appropriate during perimenopause?
How does Selank interact with female hormonal cycling?
How does Selank's half-life affect dosing?
Start a Selank Protocol
Alukard provides physician-supervised women's health protocols with GMP-certified Selank and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
Get ProtocolQuick Facts
- Molecular weight
- 751 Da
- Sequence length
- 7 aa
- Half-life
- CNS effect lasts hours; plasma short
- WADA
- Not on prohibited list
- FDA
- Unapproved (approved in Russia)
- Research
- Russian clinical trials in GAD
Stack Partners
All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Female Physiology Protocol for Selank
Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
HIPAA Compliant · GMP Certified · Physician Supervised